Herpes Zoster Rash

For the answer, click here.

Question 2:

NEXT QUESTION »

For the answer, click here.

Question 3:

NEXT QUESTION »

For the answer, click here.

Question 4:

Several brown, dry, asymptomatic plaques developed on the legs of a 59-year-old woman with diabetes mellitus and pulmonary sarcoidosis. The diagnosis was necrobiosis lipoidica.

NEXT QUESTION »

For the answer, click here.

Question 5:

ANSWER KEY »

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

ANSWER KEY:

Question 1. G

Question 2. B

Question 3. D

Question 4. F

Question 5. A

Related Content

January 17th 2025

Obesity & Type 2 Diabetes: An Expert Discussion

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

June 30th 2023

CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

January 16th 2025

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.

July 22nd 2022

GLP-1/GIP Dual Agonist HRS9531 Shows Promising Phase 2 Data for Obesity Management

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

January 15th 2025

Phase 2b Clinical Trial of Rezpegaldesleukin in Atopic Dermatitis Achieves Target Enrollment

More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.

January 13th 2025

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

Nektar Therapeutics announced the milestone in its clinical program to evaluate the IL-2 receptor agonist, a potential first-in-class treatment for the chronic condition.

Related Content

January 17th 2025

Obesity & Type 2 Diabetes: An Expert Discussion

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

June 30th 2023

CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

January 16th 2025

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.

July 22nd 2022

GLP-1/GIP Dual Agonist HRS9531 Shows Promising Phase 2 Data for Obesity Management

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

January 15th 2025

Phase 2b Clinical Trial of Rezpegaldesleukin in Atopic Dermatitis Achieves Target Enrollment

More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.

January 13th 2025